11:45 AM EST - Cardiome Pharma Corp. : Announced the publication of results from an open label, single-center, single-arm study conducted by independent researchers at the Hospital Arnau de Vilanova in Valencia, Spain, with the objective of reporting their experience of using BRINAVESS® in atrial fibrillation patients eligible to receive the drug in the emergency department setting between Jan 2014 to Dec 2015. Cardiome Pharma Corp.
shares T.COM are trading down $0.01 at $6.31.
